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Purpose: New technology based firm (NTBF) survival and growth are connected
with strategic partnering alliances and open innovation within technology clusters.
Strategic partnerships in the biotechnology industry allow new technology based
firms to gain a foothold in this high-cost, high-risk industry.
In this article, we examine the impact of strategic partnerships and open innovation
on the success of new biotechnology firms in Belgium by developing multiple case
studies of firms in regional biotechnology clusters.
A longitudinal follow up of the Belgian biotech startup ecosystem is presented. We
find that, despite their small size and relative immaturity, new biotechnology firms
are able to adopt innovative business models by providing R&D and services to
larger firms and openly cooperating with them through open innovation.
Design/methodology/approach: This is a theory-driven paper with suggested
theoretical model and case study research design.
Originality/value: Although the literature on strategic partnerships is well
developed, the majority of studies focus on large, established firms. There is
absence of studies that look at strategic partnerships – and specifically the role
of open innovation – in the development of small and innovative biotechnology
firms. This article addresses this gap in the literature with a focus on new firms
in the biotechnology cluster in Belgium, where there is a growing trend towards
technological and market-driven relationships between large and small
biotechnology firms.
Practical implications: Our conclusion is that the future of new biotechnology
firms in Belgium lies in the effective establishment of strategic partnering
alliances. In future research, the impacts of open innovation and novel business
models warrant further attention.
Keywords: New technology based firms; New biotech firms; Strategic alliances/
partnerships; Open innovation; Regional system(s) of innovation2015 Segers. Open Access This article is distributed under the terms of the Creative Commons Attribution License (http://
reativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
rovided the original work is properly credited.
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The application of new discoveries and advances in science towards commercial use
and for public purposes depends mainly upon actions by entrepreneurs who create new
technology-based firms.
Whether a broad or narrow definition is used, the evidence shows that new technol-
ogy based firms constitute only a small proportion of the firms established each year in
Belgium and in Europe. According to Storey and Tether (1998), NTBFs are thought to
embody the technologies of the future which will provide secure employment oppor-
tunities for several generations. The quality of jobs provided in NTBFs are also thought
to be significantly better than those in traditional activities.
There is also the role of NTBFs in industrial networks and technology clusters, in
which they are thought to play an important part in the transfer of technologies and in
strengthening the industrial fabric. However, in the life sciences industry (pharma, health-
care, biotechnology, medical devices, diagnostics) the high cost of commercialization make
it unlikely that any new, small firm can succeed on its own. To overcome this challenge,
many smaller firms enter into strategic partnership alliances with larger firms.
Although the literature on strategic partnerships is well developed, the majority of
studies focus on large, established firms. There is absence of studies that look at stra-
tegic partnerships – and specifically the role of open innovation – in the development
of small and innovative biotechnology firms. This article addresses this gap in the litera-
ture with a focus on new firms in the biotechnology cluster in Belgium, where there is a
growing trend towards technological and market-driven relationships between large and
small biotechnology firms.
For this research, a sample of stock-exchange-listed biotechnology firms in Belgium
are screened and monitored. Most of these new biotechnology firms are unlikely to
become fully integrated pharmaceutical companies, because they are heavily dependent
on their large strategic partners, especially for:
 marketing outlets;
 resource manufacturing when they reach the commercialization stage;
 continuing product development efforts;
 licensing agreements;
 milestone payments.
Product and market characteristics, affecting firms’ financing options, are im-
portant enablers or inhibitors (Knockaert et al., 2015). While aiming for sustain-
able growth, most of the new biotechnology firms in Belgium have not yet
reached this level of maturity and are acutely aware of the possibility of takeover.
The objective of this article is to develop an understanding of how strategic part-
nerships influence the development of these new and innovative biotechnology
firms and the role that open innovation might play in the success of these
relationships.
Research methodology
This study is structured as follows. The first section provides an overview – supported by
the literature - of biotechnology business models to show how strategic
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the regional system of innovation policy framework. In the second section, we ex-
plore the biotechnology cluster in Belgium and present the longitudinal case based
evidence for this cluster.
To investigate the impact of strategic partnering – and specifically the role of open
innovation – on the growth and survival of new biotechnology firms, we employed a
qualitative case study research design (Yin, 2009).
Our focus is new technology based firms - in particular new biotechnology firms -
operating within the regional biotechnology clusters in Belgium. The data and findings
are derived from personal interviews, company and public sector reports, IPO prospec-
tuses, financial media coverage, OECD REGPAT databases, OECD and EU Outlooks
and other available secondary data.Methods
Biotechnology cluster in Belgium: the regional framework
Science and technology offer tremendous opportunities to innovate.
Biotechnology is defined as the application of science and technology to living or-
ganisms, as well as parts, products and models thereof, to alter living or non-living
materials for the production of knowledge, goods and services. A number of bio-
technological fields that have traditionally been distinguished include health, agri-
culture, food and beverages processing, natural resources, environment, industrial
processing and bioinformatics (OECD 2009a). Next generation biotechnology opens
new frontiers in personalized medicine, advances in imaging and the use of powerful
bioinformatics.
The emphasis of this study is specifically on the valorization of red biotechnology.
Red biotechnology brings together all those biotechnology uses connected to
medicine. Red biotechnology includes producing vaccines and antibiotics, develop-
ing new drugs, molecular diagnostics techniques, regenerative therapies and the de-
velopment of genetic engineering to cure diseases through genetic manipulation.
Some relevant examples of red biotechnology are cell therapy and regenerative
medicine, gene therapy, novel scaffolds, genomics, biomarkers, companion diagnos-
tics and medicines based on biological molecules such as therapeutic antibodies.The new biotech(nology) firm (NBF)
Biotechnology firms use biotechnology to produce goods or services and/or to per-
form biotechnology R&D. Dedicated biotechnology firms are a subgroup of the bio-
technology R&D firm. They devote at least 75 % of their production of goods and
services - or R&D - to biotechnology.
A dedicated biotechnology firm is defined as a biotechnology active firm whose pre-
dominant activity involves the application of biotechnology techniques to produce
goods or services and/or the performance of biotechnology R&D.
The central task of most biotech companies is the development of drugs or new
diagnostic methods. The large majority of firms working in medically oriented bio-
technology are either still in the preclinical stage of therapeutical research or devel-
oping technology platforms in modern drug development. In general, biotechnology
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ceutical companies take the new drug through phases II-III(IV, post-approval) and
market it globally.
According to the OECD key biotechnology indicators (2009b); OECD 2011a; OECD
2013), the number of biotechnology firms is the most widely available indicator but it
is not the best measure of a country’s activity in biotechnology, owing to large differ-
ences in firm size and R&D intensity.
Business enterprise research and development expenditures on biotechnology as a
share of total business sector R&D expenditure (BERD) is an indicator of a country’s
research effort. On average, it accounted for 5.7 % of BERD in 2009 and 5.9 % in
2011. With 19.4 % in 2011, Denmark spent the most on biotechnology R&D as a
percentage of BERD, followed by Ireland (17.2 %), Switzerland (12.6 %) and Belgium
(12.6 % in 2009).
The revealed technological advantage as defined by OECD is a country’s share of
patents in a particular technology field divided by the country’s share in all patent
fields. The index is above 1 when a positive specialisation is observed. In this regard,
Denmark has the largest specialisation ratio in biotechnology followed by Singapore
and Belgium.
An alternative measure of research focus on biotechnology is biotechnology R&D
intensity, defined as biotechnology R&D expenditure as a share of total value
added of the industry sector. This ratio was 0.31 % for the USA, followed by
Switzerland (0.28 %), Ireland (0.27 %), Belgium (0.26 %) and Sweden (0.24 %).
Next to the United States (>40 %), Denmark, Belgium, Singapore and Canada all
have a strong revealed technological advantage in biotechnology with more than
10 % of their patent portfolio dedicated to biotechnology.
With lesser, but bigger New Biotechnology Firms compared to its neighbour-
countries, Belgium accounts for about 350 NBF’s, i.e. 7 % of European biotech
firms and 10 % of R&D expenditures (OECD 2011b; OECD 2014).
Within Europe, Sweden is frontrunner when it comes to public biotech market value.
Belgium is in second place. Based on average market value per company, Belgian public
biotech companies even rank first.Suggested model
One of the primary concerns is to design a theoretical model or framework that
capture(s) the real world of New Technology Based Firm-creation in Belgium. The
validity of the model is supported by empirical observations and cased based evidence
for New Biotech Firms.
The collaboration and strategic partnerships between universities and research insti-
tutions on the one hand, and the big pharmaceutical companies and biotechnology
industry on the other hand opens up opportunities for the translation of innovative
(academic) research into potential drugs, new therapies and medical diagnostics.
We screened a sample of stock-exchange listed new biotechnology firms (Table 1),
which are representative for the Belgian biotechnology cluster and for the different
business models described. These NBFs are representative for the different business
models described.





% dedicated Year Type of firm
United States 6,862 2,178 31.7 2011 Biotech R&D firms
Spain 3,070 625 20.4 2012 Biotech firms
France 1,950 1,284 65.8 2012 Biotech R&D firms
Korea 937 370 39.5 2012 Biotech firms/Dedicated
biotech R&D firms
Germany 700 570 81.4 2013 Biotech firms
UK 614 #N/A #N/A 2013 Biotech firms
Japan 552 #N/A #N/A 2013 Biotech firms
Australia 527 384 72.9 2006 Biotech firms
New Zealand 369 135 36.6 2011 Biotech firms
Belgium 350 127 36.3 2011 Biotech firms/Dedicated
biotech R&D firms
Italy 300 166 55.3 2011 Biotech firms/Dedicated
biotech R&D firms
OECD (2014), Key Biotechnology Indicators, http://oe.cd/kbi, October (adapted)
Segers Journal of Global Entrepreneurship Research  (2015) 5:16 Page 5 of 17We expect to find that:
Proposition ① New biotechnology firms in the Belgian cluster will have to work to-
gether with international (bio)pharmaceutical firms to create substantial added value;
Proposition ② The success of future new biotechnology firms in Belgium will depend
on setting up strategic partnering alliances and accommodating open innovation;
Proposition ③ Most of the new biotechnology firms in Belgium are unlikely to
become fully integrated pharmaceutical companies, i.e. they are unlikely to adopt a
product-based business model Fig. 1.
Biotechnology business models
To varying degrees, new biotechnology firms depend on strategic (technology) partnerships
with other organizations or large firms. In most of the partnerships, the initial research and
innovation developed by the smaller firms is transferred to their larger counterparts.
According to Contracter and Lorange (1988; 2002), the term alliances covers several
governance modalities ranging from relational contracting to licensing, to logistical supply-
chain relationships, to equity joint ventures or to the complete merger of two or more
organizations.
According to Porter (1985), “the business model outlines how a company generates
revenues with reference to the structure of its value chain and its interaction with the
industry value system”. In the biotechnology industry, the business model for a new,
small company is necessarily dependent on collaboration with other organizations. As
Fisken and Rutherford (2002) explain: “for a biotechnology company, the business
model serves to secure value from the company’s proprietary technology and know-
how and is currently often heavily reliant on large (bio)pharmaceutical or established
biotechnology company customers, collaborators and partners”.
Biotechnology companies have traditionally used a variety of business models to enter
the life sciences, pharmaceutical, or healthcare markets. Fisken and Rutherford (2002)
and Pareras (Pareras 2008a) distinguish between three key business models based on
the value chain structure of the biotechnology industry:
Table 1 Belgian New Biotechnology Firms (red biotech) & Strategic Partnership Alliances
Firm Name Technology Platform Product/Portfolio Strategic Partnerships/Alliances Acquisitions/Takeovers Location Region
ThromboGenicsa
Oncurious
Ophthalmic medicines Jetrea Alcon (Novartis)Novartis Flanders (Leuven)
Oncology Bioinvent Int. AB
Ablynxa Nanobodies Alpha-pharmaceuticals
Caplacizumab Ozoralizumab
Merck & Co.; AbbVie; Eddingpharm;
Novartis; Merck Serono; Shire; Eli Lilly;
Algeta Genzyme; Taiso
Flanders (Gent)
Argen-Xa Nanobodies Lonza (GS Xceed)LEO Pharma Flanders (Gent)
Galàpagosa Rheumatoid arthritis Filgotinib AbbVieGlaxoSmithKlineEli LillyJanssen
Pharmaceuticals (J&J) Servier Roche
Ono Pharmaceuticals
01/2013: acquisition of Cangenix
(drug discovery) Biofocus + Argenta:
drug discovery divisions (sold)
Flanders (Mechelen)
Tigenixa Stem cellsCell therapy ChondroCelec Cx601 Cellerix/Grifols Lonza Cellerix (acquisition) Flanders (Leuven)
Movetis Gastroenterology Resolor Shire-Movetis 2010: public takeover by Shire Flanders (Turnhout)
Genticela Therapeutic vaccines ProCervix (HPV) Paris and Toulouse (France)
Bone Therapeuticsa Stem cellsCell therapy PreobAllob Wallonia (Gosselies)
Promethera
Biosciences
Stem cellsCell therapy ShireBoehringer Ingelheim Wallonia (Louvain-L-N)
Celyada (Cardio3
BioSciences)
Stem cellsCell therapy C-Cure Oncyte (Celdara Medica, USA) Wallonia (Mont-Saint-Guibert)
Mithraa Pharmaceuticals Intrauterine platform Estelle (Estetrol) GlaxoSmithKline Wallonia (Liège)
Uteron Pharma Intrauterine platform 2013: Actavis (USA) <> 2015: buy back Wallonia (Liège)
MastherCell Stem cellsCell therapy Orgenesis (USA) Wallonia (Gosselies)
MDxHealtha Molecular diagnostics ConfirmMDx Exact SciencesOncgnostics Wallonia (Liège)













Table 1 Belgian New Biotechnology Firms (red biotech) & Strategic Partnership Alliances (Continued)


















Fig. 1 theoretical model. RSI: regional system of innovation
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pharmaceutical company", where medicines are developed by the company from
the point of discovery up to the end of clinical trials or up to approval. According
to Fisken and Rutherford (2002) this business model “aims to generate value in
progressing products along the drug development process and either licensing them
out to pharmaceutical and top tier biotechnology companies or taking them
straight through to commercialization.”
2. Platform-based: with this business model, companies develop a set of tools or
integrated technologies and license them out. Revenue can be generated relatively
quickly through contract research and services. Thus, this business model reduce
risk and the need for venture capital. Parares (Pareras 2008b) calls companies
following this model “royalty income pharmaceutical companies”. These small
companies research and develop a new drug, which they eventually license to a
large pharmaceutical company in exchange for a royalty on sales.
3. Hybrid: this is the dominant business model in the biotechnology industry. It is
a hybrid of the product-based and platform-based business models and focuses
on generating a pipeline of products. Investors benefit from reduced risks and
the possibility of near-term revenue generation. In the hybrid business model,
technology platforms are combined with services and the creation of products.
The choice of business model may depend on the type of innovation; indeed, Pisano
(2006) distinguishes between “types of pharmaceutical innovations which call for verti-
cal integration and which call for alliance-building and R&D outsourcing”. However,
for new, small technology companies the high risk and high cost of developing and
commercializing a new product on their own make the platform-based and hybrid busi-
ness models attractive.
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therapeutic products in the value creation chain. In their distributed partnering
model for drug discovery and development, product definition companies (PDC)
focus solely on advancing a portfolio of discoveries through the initial definition re-
search phase. PDCs would acquire early stage discoveries from research institutions
and invest in defining product applications with a goal of selling the successful ones
to pharmaceutical companies for further development and delivery. The PDC busi-
ness model focuses on identifying and licensing promising discoveries from research
institutes (and biotech/pharma).
Open innovation
Companies are increasingly forced to join forces in complex regional innovation net-
works or startup/ spinoff ecosystems where they organize open innovation activities.
Open innovation and open business models are two concepts that have been launched by
Henry Chesbrough (2003; 2006). It is a popular approach within innovation practice, in con-
trast to the traditional closed innovation strategies.
Oakey (2013) criticizes Chesbrough for exaggerating the applicability of open
innovation systems because R&D is often long-term, expensive and always risky and
requires necessary protection of outcomes. He argues that closed innovation is still an
effective way for R&D investment (Hossain, 2015).
“Open Innovation is a new paradigm that assumes that firms can and should use
external ideas as well as internal ideas and internal and external paths to market, as the
firms look to advance their technology”. Open innovation is defined as “the use of pur-
posive inflows and outflows of knowledge to accelerate internal innovation, and extend
the markets for external use of innovation, respectively” (Chesbrough et al., 2006). It
implies collaborating with researchers, customers, suppliers – even competitors – as
well as research institutions and universities.
The central idea behind open innovation is that, in our knowledge society, companies
cannot afford to rely entirely on their own research, but should instead buy or license
processes or inventions (e.g. patents) from other companies. In addition, internal inven-
tions not being used in a firm’s business should be taken outside the company (e.g.,
through licensing, joint ventures, spin-offs).
Various network forms of cooperation thus come into play to support the value
creation process, such as strategic alliances, consortia, ecosystems and business/tech-
nology platforms.
At the heart of the open innovation model is the recognition that today, competitive
advantage often comes from inbound as well as from outbound connections. Lever-
aging inbound connections means leveraging the discoveries of others: companies
should not rely exclusively on their own R&D. Leveraging outbound open innovation
means that, rather than relying entirely on internal paths to market, companies can
look for external organizations with business models that are better suited to
commercialize a given technology (Chesbrough, 2002).
The adoption of open innovation may be sequential, starting with customer involve-
ment, followed by employee involvement and external networking, and ending with
more “advanced” practices such as IP licensing, R&D outsourcing, venturing, and exter-
nal participations (Van de Vrande et al., 2009).
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as the motives for, and the impacts of, collaboration (Contractor & Lorange, 1988; Segers,
1993). According to Solesvik & Westhead (2010), selection of the right partner is probably
the most crucial aspect of open innovation success.
In most traditional partnerships, smaller firms perform research and development for the
larger firms or transfer innovations to them. However, open innovation is changing the way
these firms interact. In the early stages of R&D, open innovation offers a neutral platform
for companies to jointly investigate new and emerging technologies and applications, while
sharing risks and costs.
The open-innovation approach is providing new ways for firms of all sizes to collaborate,
and it is creating opportunities for smaller companies. According to Weverbergh (2013),
“cross pollination between the corporate and the startup world – whether through
corporate accelerators, venturing or open innovation – is fast becoming the trend”.Open innovation and biotech clustering
The work of Su and Hung (2009) defines five critical success factors in the evolutionary
process of a biotech cluster: (1) a strong science and industry base; (2) finance support-
ing mechanisms; (3) entrepreneurship; (4) social capital; (5) networking; with the later
three factors being intertwined.
Davies et al. (2015) examine models of life sciences startups through presenting a sci-
ence base in its role to facilitate new enterprise, alongside networking efforts to
strengthen the region.
Basically, biotech firms have worked with the open innovation concept for many years
now, using knowledge existing inside and outside the organisation. The new approach is
that of clustering and intensive partnering. A number of recent examples underline this:○ Johnson & Johnson’s pharmaceutical division, Janssen (Belgium), opened “Janssen
Labs” (J&J, 2015) (i.e. concept labs and open collaboration spaces) in San Diego, Boston
and Beerse (Belgium). This shared laboratory – and its open-plan office space –provides
life-science entrepreneurs with an affordable environment for early-stage research and
encourages interaction between startups. It enhances sourcing external innovation.
○ Roche (Pharmaphorum (2015)) announced a new open innovation research alliance
in biotechnology, nanotechnology and engineering to develop new and faster
diagnostic tests. Roche is working together with Biomed X, a new open innovation lab.
It hopes to produce speedier diagnosis and synergies with its drug treatments.
○ Open source biotechnology in big pharma with open access to data, i.e. sharing of
clinical trial data or data on newly approved medicines to researchers. This is already
the case for Pfizer, Novartis, Sanofi, GSK, Johnson & Johnson.
○ The Innovative Medicines Initiative (2010) http://www.imi.europa.eu/ is the largest
public-private partnership aiming to boost pharmaceutical innovation in Europe
and to speed up the development of better and safer medicines for patients. IMI is a
joint undertaking between the European Union and the pharmaceutical industry
association EFPIA. Large biopharmaceutical companies and small- and medium-sized
enterprises are working together with patients’ organisations, research organisations,
hospitals, regulatory agencies and other industrial partners.
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The number of strategic partnerships between large, established firms and NTBFs has
multiplied over the past decades, due to a growing trend towards technological and market-
ing relationships between large and small firms. The issue of the clustering of NTBFs relates
to agglomeration economies, especially with regard to access to knowledge and information.
Proximity is generally thought to enhance both formal and informal knowledge and infor-
mation flows, between NTBFs and both universities/research institutes and other firms,
especially the NTBFs customers which tend to be large firms. This in turn relates to the
issue of networking, and the dynamic complementarities (Rothwell, 1983) between small
and large firms in innovation. It is therefore the concept of strategic alliances, between small
and large firms, with mutual benefits for both, which is stressed here.
(O’Doherty 1990a; 1990b) argues that “strategic partnerships and alliances perhaps
represent the greatest need but also the greatest challenge for small firms and small
countries”. The challenges include both determining the strategic direction of the firm
but also finding "suitable and willing" partners to collaborate with. In the biotechnology
industry, open innovation might have a role play in meeting these challenges and in the
success of the strategic partnerships, both from the perspective of new, small compan-
ies and established, large companies. As Nigel Sheail (Bayer Healthcare, 2012) says: "Part-
nering and even open innovation is becoming increasingly important for our industry in a
world where health systems are undergoing profound transformations." According to the
Holst Centre (2013), an independent open-innovation R&D centre, “due to the increased
complexity of physics, life-sciences, materials, electronics, software, etc., the cost of R&D is
growing faster than company revenues. The goal of partnering is to share ideas and efforts,
cost and risk of R&D and to reduce the time to market of new product generations”.
In most traditional partnerships in the biotechnology industry, smaller firms perform
research and development for the larger firms or transfer innovations to them. However,
open innovation is changing the way these firms interact. In the early stages of R&D, open
innovation offers "a neutral platform for companies to jointly investigate new and emerging
technologies and applications, while sharing risks and costs" (Holst 2013).
Regional systems of innovation - innovation ecosystems
Widespread research emphasizes the role of regional systems of innovation (RSI) in aug-
menting the competitiveness and performance of regions and companies. RSI can be
defined as the “.. wider setting of organisations and institutions affecting and supporting
learning and innovation in a region” (Asheim, 2009). The regional production structure or
knowledge exploitation subsystem often displays clustering tendencies (Asheim & Gertler,
2006). Cooke (1992) in particular has pioneered the concept of the RSI.
Cooke et al. (2006) described the emergence of the Welsh Regional Science Policy
which placed life Sciences and health as a challenge area to be tackled though the EU
approach of Smart Specialisation, and the associated concentration of investment into
excellence. The mix of industry and cluster policy development objectives was dis-
cussed by Cooke (2004) and more recently by Ketels (2013). Cooke and Leydesdorff
(2006) point to the creation of infrastructure of excellence to provide basic and applied
research capabilities, and in turn construction of regional competitive advantage.
Klepper (2011) points at the valuable agglomeration economies and the Marshall
(1920) theory that suggests that firms cluster geographically because it is beneficial in
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inputs), and knowledge spillover from competing firms. Clustering facilitates learning from
other firms, lowers transaction costs for firms and suppliers and enhances productivity.
According to Klepper, the following patterns are expected in industries subject to
clustering:
 clusters begin with a successful diversifier;
 clusters experience a high rate of spinoffs;
 the leading firms in clusters are predominantly spinoffs of other leading firms in the
cluster;
 spinoffs in clusters are more competent on average than spinoffs elsewhere and/or
new firms/startups.
According to Edquist (2005), the system of innovation approach focuses on the fact
that firms do not innovate in isolation but rather in collaboration and interdependence
with other organizations such as other enterprises, universities and government
research institutes.
The Innovation Ireland Report (2010) sums up the following elements that make up
an innovation ecosystem:
 entrepreneurs and enterprises;
 investment in R&D
 education system, in particular higher education institutions;
 risk capital;
 tax and regulatory environment;
 public policy and institutions;
 international networks.
A successful innovation policy requires all elements of the ecosystem to co-operate
and collaborate together. This is in line with the “triple helix”-model by Etzkowitz &
Leydesdorff (1997; 2000) which creates constructive and mutually reinforcing activities
between academia, government, and industry.
According to Leten et al. (2013), innovation ecosystems generate value for partners by
reducing development costs and risks and by combining complementary knowledge,
enabling partners to address problems with high complexity. Ecosystem partners can subse-
quently use the knowledge created within ecosystems to support their own businesses.
Country-specific institutional features support or impede the accumulation and diffu-
sion of knowledge between the scientific and industrial communities.
Clusters, taken as concentrations of “interconnected companies and institutions in a
particular field” (Porter, 1998) continue to be of interest to policymakers.
Biotechnology clustering in Belgium is the result of a longitudinal”regional systems of
innovation” approach in the Flanders, Brussels and Walloon regions (Segers, 1996).
The region-specific technology policy in Belgium (Segers, 1992) has been organized
around two focal points:
 the existence of state-of-the-art research potential in the country's universities and
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(Segers, 1993).
Over the years, a wide range of incentives have been created for assisting new
technology-based firms. The main categories are:
○ financial and fiscal incentives (e.g., the Belgian patent income deduction regime)
○ employment incentives
○ access to seed, venture, and growth capital
○ government-supported laboratories and industry-specific collective research centres
○ technology clusters and infrastructural incentives
○ establishment of incubators in the proximity of universities for stimulating and
assisting university spin-offs
The critical success factors are:
○ access to key scientific personnel and mobility of researchers
○ access to seed and venture capital
○ the number of initial public offerings (IPOs)
○ operating losses in the early stages of development
○ regulatory approval from the Food and Drug Administration (FDA; http://
www.fda.gov/) in the United States and from the European Medicines Agency (EMA;
http://www.ema.europa.eu/ema/) in the European Union
○ patents and intellectual property rights
○ dependence on the strategic large partner(s)
○ expected revenues derived from the strategic large partner(s) (e.g., milestone
payments)
○ manufacturing, clinical trial and regulatory compliance capabilities
The life sciences and biotechnology industry have become important regional clusters
of new economic development in Belgium, and many new biotechnology firms in
Belgium are university spin-offs. Due to strong collaboration between research insti-
tutes, universities, venture capitalists, high-risk finance providers, and existing large
companies (big pharma), strong biotechnology clusters have developed in the regions
of Flanders (e.g. Ghent and Leuven) and Wallonia (e.g. Liège and Louvain-La-Neuve).
The Belgian biotechnology industry is now firmly positioned as a key player in Europe,
with a market capitalization of about 30 % in the eurozone.Results and discussion
Case study results
Within Belgium’s strong regional biotechnology clusters, we found a large number of
strategic technology partnerships between large, international, and established chemical
or (bio)pharmaceutical firms and new biotechnology firms (Segers, 2013).
Table 1 lists a sample of biotechnology firms, along with details on their strategic
partnership alliances.
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capitalists, high-risk finance providers, existing large companies, and new biotechnol-
ogy firms. The basic innovative activity occurs mainly in university-based new biotech-
nology firms,(i.e., new, small firms that are spin-offs from university research centres
performing state-of-the-art research).
On the other hand, large and international chemical or (bio)pharmaceutical firms
participate in or establish joint ventures with university research centres and small,
university-based new biotechnology firms. Of the new biotechnology firms in Belgium
that were included in this study, most are unlikely to become fully integrated pharma-
ceutical companies, because they are heavily dependent on their strategic large part-
ners, especially for marketing outlets, for manufacturing resources when they reach the
commercialization stage, and for continuing product development efforts. They have to
rely heavily on licensing agreements and milestone payments.
While aiming for sustainable growth, most new biotechnology firms in Belgium have
not yet reached an independent stage of maturity and are predominantly driven by the
takeover alternative, as was the case in recent years for Movetis (takeover by Shire) and
Devgen (takeover by Syngenta). Up to this point, only ThromboGenics, Galapagos, and
UCB have succeeded in becoming mature, self-sustaining biotechnology/biopharma
firms.
ThromboGenics is a biopharmaceutical company focused on the discovery and devel-
opment of innovative medicines for the treatment of eye diseases. The company was
established in the 1980s as a spin-off of the University of Leuven. ThromboGenics de-
veloped over the years from a university spin-off to a fully integrated specialty pharma-
ceutical company. Its lead product, Jetrea (ocriplasmin), was approved by the FDA and
the EMA in 2013. The company signed an important strategic partnership with
Alcon (Novartis) to commercialize Jetrea outside the United States. Since that time,
ThromboGenics experienced difficulties in selling Jetrea and revenues and share
value dropped extensively.
Conclusions
Over the past decade, both academics and practitioners have increasingly recognized
the need for collaboration and knowledge exchange for successful business develop-
ment. The challenges are especially large in resource intensive industries, where huge
investments are needed to develop new products. The way to overcome these costs and
to stay competitive is through embracing open innovation strategies.
Companies are increasingly forced to join forces in complex regional innovation net-
works or startup/ spinoff ecosystems where they organize open innovation activities.
Both emerging companies (startups) and high-growth (technology) firms will have to
embrace open innovation to stay relevant. The open innovation approach provides
small and large firms and regions new ways and insights to collaborate in order to cre-
ate regional growth potential and mutual long term benefits. The development of
innovation ecosystems is a prerequisite for future sustainable regional growth.
Life sciences and especially the biotechnology industry have become important regional
clusters of new and sustainable economic development in Belgium. The implications for
the national and regional systems of innovation are numerous. Our case-based analysis of
the biotechnology cluster in Belgium shows that strategic technology partnerships
Segers Journal of Global Entrepreneurship Research  (2015) 5:16 Page 15 of 17between new biotechnology firms and established, large, and international (bio)pharma-
ceutical companies have a significant impact on the survival and growth of these new bio-
technology firms.
In order to achieve sustainable development, it is advisable that the clusters have
good access to scientists, that they employ the new collaborative model or open cam-
pus model where open innovation leads to creativity. It implies mobility of researchers
between companies or from universities to companies. On the firm level, it is important
that firms have multiple projects and product portfolios, high ability to adapt, and solid
technology platforms.
Our evidence supports the assertion by Fisken and Rutherford (2002): “while a small
number of companies with access to a large supply of capital may be able to complete
downstream integration and revert to the [fully integrated pharmaceutical company]
model, the majority of biotechnology companies will instead need to further develop
sophisticated relationship management skills in order to extract greater value from re-
lationships with customers, collaborators and strategic partners”.
The interplay between biotech firms, investors, universities, large and raditional
pharmaceutical companies, government regulators may lead to new business models,
organisational structures, and financing arrangements that place greater emphasis on
integration and open innovation (e.g. cross-industry collaboration, the sharing of know-
ledge and resources) instead of monetisation of intellectual property.
Our conclusion is that the future of new biotechnology firms in Belgium lies in the
effective establishment of strategic partnering alliances. In future studies, the impacts
of open innovation and novel business models warrant further attention.
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